Andere Kunden interessierten sich auch für
![Effect of Information Technology on Glycemic Control of Children]( "Effect of Information Technology on Glycemic Control of Children")
Effect of Information Technology on Glycemic Control of Children47,99 €![Glycemic biomarkers in the patients with thyroid disorder]( "Glycemic biomarkers in the patients with thyroid disorder")
Glycemic biomarkers in the patients with thyroid disorder33,99 €![Non Caloric Artificial Sweeteners (NAS) and Glycemic control]( "Non Caloric Artificial Sweeteners (NAS) and Glycemic control")
Non Caloric Artificial Sweeteners (NAS) and Glycemic control36,99 €![Gait Speed in Older Adults]( "Gait Speed in Older Adults")
Gait Speed in Older Adults27,99 €![Low Glycemic Index- Glycemic Load Diet and Diabetes Management]( "Low Glycemic Index- Glycemic Load Diet and Diabetes Management")
Low Glycemic Index- Glycemic Load Diet and Diabetes Management32,99 €![Cerebral Palsy: Locomotion, Activity and Social Participation]( "Cerebral Palsy: Locomotion, Activity and Social Participation")
Cerebral Palsy: Locomotion, Activity and Social Participation27,99 €![Family Health Strategy in relation to user care]( "Family Health Strategy in relation to user care")
Family Health Strategy in relation to user care27,99 €
This work focuses on exploring this crucial connection between family functionality and glycemic control in patients with DM2 in patients who attend the follow-up consultation at the Family Medical Unit No. 69 in Coatzacoalcos, Veracruz. Through a detailed and empirical analysis, we seek to identify the impact of family functionality on disease management. Thus, this research aims to contribute significantly to scientific knowledge and clinical practice in the field of diabetes and family health. This is an observational, retrospective, analytical, cross-sectional study conducted in the Family Medical Unit No. 69 "Marina Anaya" where patients with type 2 diabetes mellitus in the range of 30-50 years who attended follow-up consultation between December 2023 and December 2024 were included, excluding pregnant patients, with comorbidities and in insulin treatment.